All In Biotech

Drug Trial Radar · NCT07412938

JKN2306 in Healthy Subjects: Single Ascending Dose and Food Effect Study

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of Single Oral Doses of JKN2306 Tablets in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

44

Actual

Start

Feb 12, 2025

Primary completion

Jul 2, 2025

Study completion Jul 2, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This first-in-human, single-center study in China evaluated the safety, tolerability, and pharmacokinetics of single oral doses of JKN2306 tablets in healthy adult subjects and assessed the effect of a high-fat, high-calorie meal on the pharmacokinetics of JKN2306.

Conditions

  • Acute Pain

Interventions

  • JKN2306Drug

    JKN2306 tablet, oral

  • PlaceboDrug

    matching placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of single oral doses of JKN2306Time frame: SAD: Baseline to Day 8 post-dose.FE: Baseline to Day 15 post-dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.